Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Phathom Pharmaceuticals
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
June 23, 2026
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 22, 2026
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
May 20, 2026
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
May 8, 2026
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 8, 2026
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
May 6, 2026
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 5, 2026
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
April 28, 2026
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
March 10, 2026
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
March 9, 2026